For instance, when used alone, anti-PD-1/PD-L1 antibodies demonstrate clinical efficacy in only approximately 20% of non-small cell lung cancer (NSCLC) patients [3]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.